Skip to main content
    O

    OUTLOOK THERAPEUTICS INC (OTLK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.50
    +0.03 (+6.34%)

    Market Cap: $114.47M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    46%(18/39)
    Avg Surprise
    -7.29%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.08 - $-0.05
    2 analysts
    Revenue Consensus
    $-7821500
    Range$-8604170 - $-6756170
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.05
    Range$-0.08 - $-0.01
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.07+37.7%
    60d ago$-0.07+37.7%
    30d ago$-0.05+6.6%
    7d ago$-0.05+6.6%
    Current$-0.05
    Revenue Consensus
    $5M
    Range$1M - $9M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.05---
    Sep 26EST
    		-$-0.07---
    Jun 26
    Reported Aug 13
    		$-0.09$-0.09+0.00%Beat+79.5%
    Mar 26
    Reported May 15
    		$-0.17$-0.12-41.67%Miss+57.5%
    Dec 25
    Reported Feb 17
    		$-0.22$-0.17-29.41%Miss-130.6%
    Sep 25
    Reported Dec 19
    		$-0.28$-0.06-366.67%Miss+70.1%
    Jun 25
    Reported Aug 14
    		$-0.44$-0.39-12.82%Miss+47.0%
    Mar 25
    Reported May 15
    		$-0.40$-0.55+27.27%Beat+74.2%
    Dec 24
    Reported Feb 14
    		$0.72$-0.62+216.13%Beat+192.3%
    Sep 24
    Reported Dec 27
    		$-0.94$-0.90-4.10%Miss-1773.8%
    Jun 24
    Reported Aug 14
    		$-0.83$-0.84+1.19%Beat+39.9%
    Mar 24
    Reported May 15
    		$-1.55$-1.07-44.86%Miss-198.1%
    Dec 23
    Reported Feb 14
    		$-0.78$-1.07+27.10%Beat+50.9%
    Sep 23
    Reported Dec 22
    		$-0.05$-0.06+16.67%Beat+16.7%
    Jun 23
    Reported Aug 14
    		$-1.38$-0.87-58.62%Miss+11.5%
    Mar 23
    Reported May 15
    		$-0.52N/A+56.67%Beat+70.6%
    Dec 22
    Reported Feb 14
    		$-1.59$-1.30-22.31%Miss-1887.5%
    Sep 22
    Reported Dec 29
    		$-0.06$-0.07+14.29%Beat+96.3%
    Jun 22
    Reported Aug 10
    		$-1.56$-1.33-17.29%Miss-11.4%
    Mar 22
    Reported May 13
    		$-1.77$-1.20-47.50%Miss+1.7%
    Dec 21
    Reported Feb 14
    		$-0.08$-0.06-33.33%Miss+96.4%
    Sep 21
    Reported Dec 22
    		$-1.60$-1.27-25.98%Miss-1130.8%
    Jun 21
    Reported Aug 13
    		$-1.40$-1.40+0.00%Beat+36.4%
    Mar 21
    Reported May 14
    		$-1.80$-1.80+0.00%Beat+30.8%
    Dec 20
    Reported Feb 16
    		$-2.20$-1.65-33.33%Miss+60.7%
    Sep 20
    Reported Dec 23
    		$-0.13$-0.08-62.50%Miss-8.3%
    Jun 20
    Reported Aug 14
    		$-2.20$-1.90-15.79%Miss+54.2%
    Mar 20
    Reported May 15
    		$-2.60$-2.45-6.12%Miss+86.5%
    Dec 19
    Reported Feb 14
    		$-5.60$-4.40-27.27%Miss+61.1%
    Sep 19
    Reported Dec 19
    		$-0.12N/A+61.29%Beat+62.5%
    Jun 19
    Reported Aug 14
    		$-4.80$-7.27+33.98%Beat+85.0%
    Mar 19
    Reported May 15
    		$-19.26$-13.20-45.91%Miss+62.4%
    Dec 18
    Reported Feb 14
    		$-14.40N/A+70.97%Beat-480.6%
    Sep 18
    Reported Dec 18
    		$-0.32$-0.23-39.13%Miss+99.1%
    Jun 18
    Reported Aug 14
    		$-32.00$-36.80+13.04%Beat+46.1%
    Mar 18
    Reported May 15
    		$-51.20$-36.80-39.13%Miss+16.4%
    Dec 17
    Reported Feb 14
    		$-2.48$-1.92-29.17%Miss+98.1%
    Sep 17
    Reported Dec 29
    		$-35.76N/A+63.95%Beat-
    Jun 17
    Reported Aug 14
    		$-59.42$-102.40+41.97%Beat-
    Mar 17
    Reported Jun 28
    		$-61.25N/A+59.70%Beat-
    Dec 16
    Reported Feb 14
    		$-131.20$-153.60+14.58%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.66EV/EBITDAN/A
    Price/FCF-0.22xFCF Yield-448.51%
    Profitability
    Profit Margin0.00%Operating Margin-124255.00%
    ROE-3.65%ROIC-776.89%
    Financial Health
    Debt/Equity-1.75xInterest Coverage-2.80x
    Current Ratio0.81xQuick Ratio0.63x
    Trading Statistics
    Beta0.67Avg Volume4.67M
    52-Week High$2.5452-Week Low$0.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.56
    SMA 20$0.60
    SMA 50$0.68
    SMA 200$0.68
    EMA 10$0.56
    EMA 20$0.59
    EMA 50$0.70
    EMA 200$0.86

    MACD

    Line: -0.05Signal: -0.05Hist: -0.00

    ADX

    ADX: 23.3+DI: 11.7-DI: 35.8

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down100.0
    PSAR$0.63

    Bollinger Bands

    Upper Band$0.71
    Lower Band$0.49
    %B Position3771%(Upper)
    Band Width0.05

    RSI (14-Day)

    Neutral
    33.9

    Momentum Oscillators

    Stoch %K17.7
    Stoch %D21.8
    Williams %R-69.0
    ROC (10d)-13.0%
    Momentum-0.07
    CCI (20d)-186.0
    MFI (14d)32.9

    Volatility Measures

    ATR (14d)$0.05(10.5%)
    StdDev (20d)0.06
    Hist Vol85.0%(High)

    Volume Flow

    VWAP$0.48
    OBV113.9M
    AD Line-273.8M
    CMF (20d)-0.232

    Volume Metrics

    Avg Vol (20d)4.6M
    Vol Ratio1.1x
    VWMA (20d)$0.59

    Pivot Points

    R3$0.63
    R2$0.60
    R1$0.53
    Pivot Point$0.50
    S1$0.44
    S2$0.41
    S3$0.34

    Advanced Oscillators

    TSI-28.23
    Ultimate Osc44.6
    KST-140.39

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9,000$127,439$-1,207,833$-91,787$1.51M$0$170,124$170,124$0$0$0$0
    Cost of Revenue$17,000$149,327$29,626$916,515$439,815$29,102$28,801$28,797$28,672$28,195$28,195$11,217
    Gross Profit$-8,000$-21,888$-1,237,459$-1,008,302$1.07M$-29,102$-28,801$-28,797$-28,672$-28,195$-28,195$-11,217
    Operating Expenses$10.80M$14.01M$12.25M$16.31M$16.81M$12.39M$21.58M$22.85M$19.56M$18.94M$10.32M$12.46M
    R&D$3.25M$4.50M$3.63M$5.98M$7.13M$4.41M$9.66M$12.52M$11.20M$13.51M$4.53M$4.94M
    SG&A$7.55M$9.50M$8.61M$10.33M$9.68M$7.98M$11.95M$10.35M$8.36M$5.43M$5.79M$7.51M
    Operating Income$-10,810,000$-14,026,987$-13,483,952$-17,314,606$-15,748,680$-12,391,528$-21,606,852$-22,877,451$-19,562,687$-18,939,975$-10,323,000$-12,459,000
    Interest Income$0$0$0$0$0$0$48,881$239,951$404,593$0$0$0
    Interest Expense$9.47M$3.00M$9.57M$264,156$49,351$18,502$0$72.93B$0$3.08M$2142.77B$2142.77B
    Income Before Tax$-20,278,000$-4,453,081$-23,058,135$-14,847,398$-20,152,502$-46,354,406$17.38M$5.69M$44.41M$-114,286,143$-11,178,000$-12,991,000
    Income Tax Expense$41,000$0$0$-1,554,629$0$2,800$17377.60B$0$-2$2,800$-135,335$2.80B
    Net Income$-20,319,000$-4,453,081$-23,058,135$-13,292,769$-20,152,502$-46,357,206$17.38M$5.69M$44.41M$-114,288,943$-11,178,000$-12,991,000
    EBITDA$-20,264,209$-13,996,570$-13,453,878$-14,553,505$-20,073,739$-12,362,426$-21,578,000$-22,848,654$-19,534,015$-18,911,780$-10,295,000$-16,742,000
    EBIT$-20,278,000$-14,026,987$-13,483,952$-14,583,242$-20,103,151$-12,391,528$-21,606,801$-22,877,451$-19,562,687$-18,939,975$-10,323,195$-16,753,217
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OTLK

    News

    Outlook Therapeutics stock costs EUR 0.44, volume 59.0 percent below average

    On October 15, 2026, Outlook Therapeutics stock traded at EUR 0.44 with a volume of 5,318,221 shares, which was 59.0 percent below its average. The company, focused on ophthalmic medicines and commercializing LYTENAVA...

    ad-hoc-news.de•10/15/26•Neutral

    Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK).

    Empery Asset Management, LP and Ryan M. Lane have reported a shared beneficial ownership of 21,247,856 shares, or 8.73%...

    Stock Titan•10/13/26•Neutral

    Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

    Outlook Therapeutics has appointed Greg DiPasquale as its Chief Commercial Officer. DiPasquale will lead the commercialization efforts for Lytenava (bevacizumab-vikg)...

    VisionMonday.com•10/12/26•Bullish

    Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026.

    This article announces that certain common stock of Outlook Therapeutics, Inc. will be subject to a lock-up agreement ending on October 12, 2026. The lock-up period is 60 days, starting from August 12, 2026...

    www.marketscreener.com•10/11/26•Neutral

    Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer Ahead of LYTENAVA U.S. Launch

    Outlook Therapeutics (Nasdaq: OTLK) has appointed Greg DiPasquale as Chief Commercial Officer to lead the U.S. launch of its FDA-approved retinal disease treatment, LYTENAVA (bevacizumab-vikg)...

    citybiz•10/9/26•Bullish

    OTLK Valuation and Fair Value

    P/E
    -0.7x
    Forward P/E
    2.9x
    P/FCF
    -0.2x
    P/B
    -1.2x
    See GNG's fair value

    OTLK Profitability: Margins, ROIC and FCF

    Gross margin
    195.6%
    Operating margin
    -124255.0%
    Net margin
    0.0%
    ROIC
    -776.9%
    ROE
    -3.6%
    FCF yield
    -448.5%

    OTLK Competitors

    CompanyTicker
    Cassava Sciences IncSAVA
    Repare Therapeutics IncRPTX
    Seer IncSEER
    Cumberland Pharmaceuticals IncCPIX
    Tenaya Therapeutics IncTNYA
    Minerva Neurosciences IncNERV
    LifeMD IncLFMD
    TuHURA Biosciences IncHURA

    Sector: Healthcare

    OTLK Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    3
    Hold
    1
    Sell
    0
    Strong Sell
    0

    OTLK Bull Case vs Bear Case

    Bear case

    • OTLK beat EPS estimates in 25.0% of its last 8 reported quarters.
    • OTLK's quarterly revenue changed -99.4% year over year.

    OTLK Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -26.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.07

    Frequently Asked Questions About OTLK

    Does OTLK pay dividends?

    OUTLOOK THERAPEUTICS INC (OTLK) does not currently pay a regular dividend.

    What is OTLK's market cap?

    OUTLOOK THERAPEUTICS INC (OTLK) has a market capitalization of $114.47M with a current stock price of $0.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with O

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In